Anil B. Jindal

Dr. Anil B. Jindal


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AJAnil B. Jindal
Anil B. Jindal

7 May 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
AJAnil B. Jindal
Anil B. Jindal
ABAtharva R. Bhide
Atharva R. Bhide
Sagar SalaveSagar Salave
Sagar Salave
DRDhwani Rana
Dhwani Rana
DBDerajram Benival
Derajram Benival

1 June 2010 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
PDPadma V. Devarajan
Padma V. Devarajan
AJAnil B. Jindal
Anil B. Jindal
RPRajesh R. Patil
Rajesh R. Patil
FMFernaz Mulla
Fernaz Mulla
RGRajiv V. Gaikwad
Rajiv V. Gaikwad
ASAbdul Samad
Abdul Samad

1 June 2017 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
HRHarshita Raina
Harshita Raina
SKSimrandeep Kaur
Simrandeep Kaur
AJAnil B. Jindal
Anil B. Jindal

1 August 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
DSDhanashree H. Surve
Dhanashree H. Surve
AJAnil B. Jindal
Anil B. Jindal

1 February 2011 in Current Nanoscience
Verified
Journal Article
Closed access
PDF file
RSRajshree L. Shinde
Rajshree L. Shinde
AJAnil B. Jindal
Anil B. Jindal
PDPadma V. Devarajan
Padma V. Devarajan
Brain disorders including neurological disorders, inflammatory and infectious conditions of brain, brain cancer and brain stroke pose a significant challenge globally. The blood brain barrier (BBB) an important physiological barrier limits access of drug to the site of action. While passive diffusion and endogenous carrier mediated transport are two important mechanisms for the transport of substances across the BBB into the luminal side, efflux transporters severely limit drug concentration. Drug delivery strategies must address on one hand methods to bypass the BBB and on the other hand methods to overcome efflux transporters. Lipid based nanocarriers, liposomes and solid lipid nanoparticles are widely investigated for brain targeting. Emulsion based lipid nanocarriers like microemulsions (ME) and nanoemulsions (NE) provide an additional advantage of greater bypass of the reticulo-endothelial system with improved brain targeting. More recently the promise of ME and NE for brain delivery has been cited. Oil, surfactants and water are the primary components of ME and NE. ME may additionally comprise cosurfactants. The reviews discusses the development of ME/NE, design of functional ME/NE by appropriate selection of primary ME/NE components which could provide improved brain delivery by functioning as stealth agent, absorption enhancer, efflux transporter inhibitor or even facilitate receptor mediated endocytosis. Engineering functional ME/NE into multifunctional ME/NE as a strategy to further enhance brain targeting is also presented. Functional and multifunctional excipients have been discussed. The possible routes of delivery namely intravenous, oral and intranasal and therapeutic applications of ME/NE designed for brain targeting is also reviewed.